Results 151 to 160 of about 2,249 (191)
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
Clinical, Cosmetic and Investigational Dermatology, 2022 Atopic dermatitis is a prevalent, inflammatory skin disease that presents with an eczematous, itchy rash. As of late, there have been many emerging monoclonal antibody inhibitor and small molecule therapies that have changed the course of eczema treatment. One of the treatments in the pipeline for atopic dermatitis is interleukin 13 monoclonal antibody
Angelina Labib +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Lebrikizumab for the treatment of asthma
Expert Opinion on Investigational Drugs, 2016In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain inflammation pathways and lebrikizumab an anti ...
Sabina A Antoniu
exaly +3 more sources
Lebrikizumab Treatment in Adults with Asthma
New England Journal of Medicine, 2011Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype.
Nicola A Hanania, Joseph R Arron
exaly +7 more sources
Lebrikizumab in the treatment of asthma
Expert Opinion on Biological Therapy, 2016Severe asthma continues to be a major clinical problem despite the availability of effective asthma medications such as inhaled corticosteroids. Several targeted biologic therapies are emerging to treat patients with severe asthma. Areas Covered: This review provides an update of information on lebrikizumab, a novel monoclonal antibody that targets IL ...
Stephen, Bujarski +2 more
openaire +2 more sources
The Role of Lebrikizumab in the Treatment of Atopic Dermatitis in the Adult Population
Immunotherapy, 2023Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD.
Stuti Prajapati +3 more
openaire +2 more sources
Drugs
Lebrikizumab (Ebglyss®) is a subcutaneous recombinant humanized IgG4 anti-IL-13 monoclonal antibody developed by Almirall S.A. and Eli Lilly and Company for the treatment of atopic dermatitis (AD). In November 2023, lebrikizumab was approved in the EU for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older with a body ...
openaire +2 more sources
Lebrikizumab (Ebglyss®) is a subcutaneous recombinant humanized IgG4 anti-IL-13 monoclonal antibody developed by Almirall S.A. and Eli Lilly and Company for the treatment of atopic dermatitis (AD). In November 2023, lebrikizumab was approved in the EU for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older with a body ...
openaire +2 more sources
pharma-kritik
Lebrikizumab: Ein Interleukin-13-Hemmer. ebenfalls mit der Indikation einer schwierig behandelbaren atopischen Dermatitis. Er ist dabei ähnlich wirksam wie andere systemisch verabreichte Wirkstoffe. Wie unter Dupilumab tritt auch unter diesem IL-Hemmer häufig eine Konjunktivitis auf.
openaire +1 more source
Lebrikizumab: Ein Interleukin-13-Hemmer. ebenfalls mit der Indikation einer schwierig behandelbaren atopischen Dermatitis. Er ist dabei ähnlich wirksam wie andere systemisch verabreichte Wirkstoffe. Wie unter Dupilumab tritt auch unter diesem IL-Hemmer häufig eine Konjunktivitis auf.
openaire +1 more source